Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MILOPHENE vs DUAVEE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
MILOPHENE is a selective estrogen receptor modulator (SERM) that acts as an antagonist in breast tissue and agonist in bone and cardiovascular tissues. It binds competitively to estrogen receptors, inhibiting estrogen-mediated proliferation in breast cancer cells.
DUAVEE is a combination of conjugated estrogens (CE) and bazedoxifene (BZA). CE activates estrogen receptors (ERα and ERβ) to relieve menopausal symptoms; BZA is a selective estrogen receptor modulator (SERM) that antagonizes ER in the endometrium to prevent endometrial hyperplasia.
Treatment of metastatic breast cancer in postmenopausal women with estrogen receptor-positive tumors,Reduction in incidence of invasive breast cancer in women at high risk (FDA-approved),Off-label: ovulation induction in anovulatory infertility
Moderate to severe vasomotor symptoms due to menopause,Prevention of postmenopausal osteoporosis
1-2 mg/kg intravenously every 4 hours, not to exceed 100 mg per dose.
One tablet (conjugated estrogens 0.45 mg/bazedoxifene 20 mg) orally once daily.
Terminal elimination half-life is 18-24 hours, supporting once-daily dosing; prolonged in renal impairment.
Conjugated estrogens: terminal half-life of estrone sulfate is approximately 10-24 hours. Bazedoxifene: terminal half-life is approximately 30 hours. Clinically, steady state is achieved within 7 days for estrogens and 10-14 days for bazedoxifene.
Metabolized primarily by CYP3A4 and CYP2D6 to active metabolites (e.g., N-desmethylmilophene, 4-hydroxymilophene). Undergoes enterohepatic recirculation.
Conjugated estrogens are primarily metabolized in the liver via phase II conjugation (sulfation and glucuronidation) by enzymes such as UGT1A1, UGT1A8, UGT1A9, UGT2B7, and SULT1A1. Bazedoxifene undergoes hepatic metabolism via glucuronidation by UGT1A1, UGT1A8, UGT1A9, and UGT2B7, with minimal CYP involvement.
Primarily renal excretion of unchanged drug (70-80%), with 10-15% as glucuronide conjugate; biliary/fecal elimination accounts for <10%.
Conjugated estrogens are primarily excreted in urine as glucuronide and sulfate conjugates, with approximately 10-15% excreted in feces via biliary elimination. Bazedoxifene is mainly eliminated in feces (85%) with minimal renal excretion (<1% as unchanged drug).
92-96% bound to albumin.
Conjugated estrogens: extensive binding to albumin (approximately 80-85%). Bazedoxifene: highly bound (>99%) to albumin and alpha-1-acid glycoprotein.
0.3-0.4 L/kg, indicating distribution primarily in extracellular fluid.
Conjugated estrogens: Vd approximately 0.5-2 L/kg, indicating distribution into total body water and tissues. Bazedoxifene: Vd approximately 1.2 L/kg, suggesting extensive tissue distribution.
Oral: 65-75% with significant first-pass metabolism.
Conjugated estrogens: oral bioavailability is approximately 30-50% due to first-pass metabolism. Bazedoxifene: absolute oral bioavailability is approximately 6% due to extensive first-pass glucuronidation.
GFR 30-50 m L/min: 75% of normal dose every 6 hours; GFR 15-29 m L/min: 50% of normal dose every 8 hours; GFR <15 m L/min: 25% of normal dose every 12 hours.
No dosage adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not recommended in severe renal impairment (Cr Cl <30 m L/min) due to lack of data.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: 50% of normal dose every 6 hours; Child-Pugh Class C: contraindicated.
Contraindicated in Child-Pugh Class C (severe hepatic impairment). Use with caution in Child-Pugh Class A or B; no specific dose adjustment established, but monitor closely.
Children 1 month to 12 years: 0.5-1 mg/kg intravenously every 4-6 hours, maximum 50 mg per dose; infants <1 month: 0.25-0.5 mg/kg every 6-8 hours.
Not indicated for use in pediatric patients. Safety and efficacy have not been established.
Start at 50% of adult dose, increase based on tolerance and renal function; monitor for neurotoxicity and QT prolongation.
No specific dose adjustment recommended. Higher risk of adverse events (e.g., thromboembolism, stroke) in women >65 years of age; use lowest effective dose for shortest duration.
Boxed Warning: Increased risk of thromboembolic events (deep vein thrombosis, pulmonary embolism) and stroke. Use with caution in patients with history of thromboembolic disorders.
Estrogen therapy increases the risk of endometrial cancer in women with a uterus. Concomitant use of a progestin or bazedoxifene is required to reduce this risk. Cardiovascular disorders: Estrogen-alone therapy may increase risk of stroke and DVT. Estrogen plus progestin therapy increases risk of MI, stroke, invasive breast cancer, pulmonary emboli, and DVT. DUAVEE is not approved for cardiovascular disease prevention. Breast cancer: Estrogen plus progestin therapy increases risk of invasive breast cancer. Probable dementia: Estrogen plus progestin therapy increases risk in women 65+.
Warnings: Thromboembolic events, stroke, endometrial hyperplasia/carcinoma, ovarian cysts, visual disturbances (e.g., cataracts, retinopathy), hepatic impairment, hypercalcemia in bone metastases. Monitor lipid profiles and liver function.
Cardiovascular disorders (stroke, DVT, MI, pulmonary embolism),Malignant neoplasms (endometrial cancer, breast cancer),Gallbladder disease,Hypertriglyceridemia,Fluid retention,Hypocalcemia,Hereditary angioedema,Exacerbation of endometriosis,Exacerbation of asthma, diabetes, migraine, porphyria, SLE, hepatic hemangiomas,Retinal vascular thrombosis
Contraindications: Hypersensitivity to milophene or any component; pregnancy (Category X); history of thromboembolic disease (e.g., DVT, PE); undiagnosed abnormal genital bleeding; hepatic impairment (severe); concurrent use of anticoagulants.
Undiagnosed abnormal genital bleeding,Known, suspected, or history of breast cancer,Known or suspected estrogen-dependent neoplasia,Active or past history of venous thromboembolism (VTE),Active or past history of arterial thromboembolism (e.g., stroke, MI),Known protein C, protein S, or antithrombin deficiency or other thrombophilic disorders,Hypersensitivity to any component,Pregnancy
Grapefruit juice may increase clomiphene levels; avoid concurrent consumption. No specific food restrictions, but maintain a balanced diet. Limit caffeine intake as it may affect fertility.
Grapefruit juice may increase estrogen levels; avoid large amounts. No other significant food interactions. Alcohol may increase risk of liver issues; limit intake.
MILOPHENE is a dopamine agonist used for hyperprolactinemia. In the first trimester, there is limited human data but no evidence of increased major malformations. Risk cannot be completely excluded. In the second and third trimesters, continued use may be justified if needed. Limited studies suggest no significant increase in adverse fetal outcomes. However, dopamine agonists have been associated with fetal harm in animal studies, so cautious use is warranted throughout pregnancy.
DUAVEE (conjugated estrogens/bazedoxifene) is contraindicated in pregnancy. Estrogens may cause fetal harm; first trimester exposure is associated with congenital anomalies including cardiovascular and limb defects. Second and third trimester exposure increases risk of urogenital abnormalities and delayed cognitive development. Bazedoxifene is a selective estrogen receptor modulator; animal studies show embryotoxicity and fetotoxicity at clinically relevant doses.
MILOPHENE is excreted into human breast milk. The M/P ratio is unknown but assumed to be low based on molecular weight and protein binding. Due to potential adverse effects on the infant (e.g., dopamine receptor blockade), breastfeeding is not recommended during therapy. Alternative treatments or cessation of breastfeeding should be considered.
Contraindicated during breastfeeding. Estrogens and bazedoxifene are excreted in human milk; M/P ratio not reported. Estrogens may reduce milk production and quality. Potential for adverse effects in nursing infants.
Pharmacokinetic changes during pregnancy (e.g., increased plasma volume, renal clearance) may require dose adjustment. However, data are limited. Clinical monitoring of prolactin levels and symptom control is recommended. Dose may need to be increased to maintain efficacy, but the lowest effective dose should be used. No specific dose adjustment guidelines exist; therefore, individualized titration based on response is prudent.
No dose adjustments applicable; do not use in pregnancy. Pharmacokinetic changes in pregnancy (increased clearance, volume of distribution) are irrelevant due to contraindication.
Milophene (clomiphene citrate) is a selective estrogen receptor modulator used for ovulation induction. Monitor for ovarian hyperstimulation syndrome (OHSS) with pelvic ultrasound. Limit course duration to 6 cycles due to increased risk of ovarian cancer. Use with caution in patients with liver disease or abnormal uterine bleeding. Administer on days 3-7 of menstrual cycle for optimal response.
DUAVEE (conjugated estrogens/bazedoxifene) is indicated for moderate-to-severe vasomotor symptoms and osteoporosis prevention in postmenopausal women with a uterus. Avoid in women with intact uterus who are not on a progestin; bazedoxifene is the progestin component. Contraindicated in women with undiagnosed abnormal genital bleeding, known/suspected pregnancy, breast cancer, estrogen-dependent neoplasia, active DVT/PE, or history of these conditions. Monitor for thromboembolic events. Not for use in women with prior hysterectomy. Discontinue if jaundice or visual disturbances occur.
Take exactly as prescribed, typically one tablet daily for 5 days starting on cycle day 3, 4, or 5.,Notify your doctor immediately if you experience severe pelvic pain, nausea, vomiting, or sudden weight gain (signs of OHSS).,Avoid pregnancy before starting treatment; use barrier contraception until instructed.,Multiple births (especially twins) occur in about 10% of pregnancies; discuss this risk.,Report any visual disturbances (blurring, spots, flashes) promptly; discontinue use if they occur.,Do not exceed 6 treatment cycles; prolonged use increases ovarian cancer risk.
Take DUAVEE once daily with or without food.,This medication is for postmenopausal women with a uterus; it contains both estrogen and a progestin-like drug to protect the uterine lining.,Do not use if you have any unexplained vaginal bleeding, are pregnant, have or have had breast cancer, blood clots, or liver disease.,Report promptly any signs of blood clots (leg pain/swelling, chest pain, sudden shortness of breath) or stroke (sudden headache, vision/speech changes).,DUAVEE may increase risk of gallbladder disease, dementia (if started after age 65), and endometrial hyperplasia if the progestin component fails.,Smoking while on DUAVEE increases risk of blood clots; avoid smoking.,DUAVEE does not prevent heart attack or stroke; in fact, it may increase cardiovascular risk, especially in older women.,Store at room temperature, away from moisture and heat.,If you miss a dose, take it as soon as possible; if almost time for the next dose, skip the missed dose and resume regular schedule. Do not double dose.,You will need regular medical check-ups including mammograms and pelvic exams.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MILOPHENE vs DUAVEE, answered by our medical review team.
MILOPHENE is a Selective Estrogen Receptor Modulator that works by MILOPHENE is a selective estrogen receptor modulator (SERM) that acts as an antagonist in breast tissue and agonist in bone and cardiovascular tissues. It binds competitively to estrogen receptors, inhibiting estrogen-mediated proliferation in breast cancer cells.. DUAVEE is a Selective Estrogen Receptor Modulator/Estrogen Combination that works by DUAVEE is a combination of conjugated estrogens (CE) and bazedoxifene (BZA). CE activates estrogen receptors (ERα and ERβ) to relieve menopausal symptoms; BZA is a selective estrogen receptor modulator (SERM) that antagonizes ER in the endometrium to prevent endometrial hyperplasia.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MILOPHENE and DUAVEE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MILOPHENE is: 1-2 mg/kg intravenously every 4 hours, not to exceed 100 mg per dose.. The standard adult dose of DUAVEE is: One tablet (conjugated estrogens 0.45 mg/bazedoxifene 20 mg) orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MILOPHENE and DUAVEE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MILOPHENE is classified as Category C. MILOPHENE is a dopamine agonist used for hyperprolactinemia. In the first trimester, there is limited human data but no evidence of increased major malformations. Risk cannot be co. DUAVEE is classified as Category C. DUAVEE (conjugated estrogens/bazedoxifene) is contraindicated in pregnancy. Estrogens may cause fetal harm; first trimester exposure is associated with congenital anomalies includi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.